Signalling Pathways in Tumor Cells to Drive Global Small Molecule Tyrosine Kinase Inhibitor Market

Published: Mar 2022

The global small-molecule tyrosine kinase inhibitor market is expected to grow at a significant CAGR  of 7.3% during the forecast period (2022-2028). TKIs (tyrosine kinase inhibitors) are small molecules that block intracellular signalling pathways in tumor cells, causing deregulation of key cell functions such as proliferation and differentiation. Furthermore, small-molecule inhibitors (SMIs) are among the most effective drugs for targeted cancer therapy, according to the National Center for Biotechnology Information (NCBI). As a result, the rising prevalence of cancer is increasing demand for small molecule tyrosine kinase inhibitors, which is propelling the global small molecule tyrosine kinase inhibitor market forward.

Browse the full report description of “Global Small Molecule Tyrosine Kinase Inhibitor Market Size, Share, and Trend Analysis Report, By Type (Phase-I, Phase-I/II, Phase-II, Phase-II/III, and Phase-III), By Application (Lung Cancer, Breast Cancer, and Others), Forecast (2022-2028)” at https://www.omrglobal.com/industry-reports/small-molecule-tyrosine-kinase-inhibitor-market

Furthermore, there were 18.1 million new cancer cases and 9.5 million cancer-related mortalities across the globe in 2020, with the number of cancer-related mortalities expected to rise to 29.5 million and 16.4 million by 2040. To stay competitive, market players are adopting various strategies such as mergers and acquisitions, geographical expansion, partnerships and collaborations, and new product launches, which contribute significantly to market growth.

Market Coverage

The market number available for – 2021-2028

Base year- 2021

Forecast period- 2022-2028

Segment Covered- 

o By Type

o By Application

Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

Competitive Landscape-Merck Group, Novartis AG, Pfizer Inc., Sanofi SA, GlaxoSmithKline plc. 

Key questions addressed by the report

What is the market growth rate?

Which segment and region dominate the market in the base year?

Which segment and region will project the fastest growth in the market?

How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

Who is the leader in the market?

How players are addressing challenges to sustain growth?

Where is the investment opportunity?

Global Small Molecule Tyrosine Kinase Inhibitor Market Report Segment

By Type

Phase1

Phase1/2

Phase2

Phase2/3

Phase3

By Application

Lung cancer

Breast cancer

Global Small Molecule Tyrosine Kinase Inhibitor Market Report Segment by Region

North America

US

Canada

Europe

UK

Germany

Italy

Spain

France

Rest of Europe 

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific 

Rest of the World

Latin America 

Middle East & Africa


To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/small-molecule-tyrosine-kinase-inhibitor-market